Journals / TSK Koruyucu Hekimlik Bülteni / 2011 / Cilt: 10 - Sayı: 5

The evaluation of the knowledge levels and attitudes of medical students who have accomplished obstetric and gynaecological diseases internship in a medical school about human papilloma virus vaccine

Bir tıp fakültesinde kadın hastalıkları ve doğum stajını yapmış öğrencilerin HPV aşısı hakkında bilgi düzeyleri ve tutumlarının değerlendirilmesi

Pages
557–564
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also we determine the most important factor in suggesting the HPV vaccine is the cost effectiveness of it.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Aim of the study was to determine medical school students’ knowledge levels and attitudes who accomplished Obstetric and Gynecology clerkship in a medical school about HPV vaccination and intention to suggest HPV vaccine to their patients.
📊
Key Findings & Data:METHOD: This descriptive study was carried out in a medical school among 166 medical students accomplishing their internship in the Obstetrics and Gynaecological Diseases Department.
💡
Conclusion & Impact:Also we determine the most important factor in suggesting the HPV vaccine is the cost effectiveness of it.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: Aim of the study was to determine medical school students’ knowledge levels and attitudes who accomplished Obstetric and Gynecology clerkship in a medical school about HPV vaccination and intention to suggest HPV vaccine to their patients. METHOD: This descriptive study was carried out in a medical school among 166 medical students accomplishing their internship in the Obstetrics and Gynaecological Diseases Department. Study data had been collected by questionnaire which had three part and 30 question. The data were evaluated by descriptive statistics. RESULTS: Fifty five point four of the students stated that they felt informed about HPV vaccine, 72.9% of them stated that HPV was more serious for women. 95.8% of the participants thought they would suggest HPV vaccine to their patients and the most proposed group was adolescent girls (51.6%). 80.5% of students stated their possibility to suggest the vaccine would increase in case the vaccine would be free. The most important drawback points of the students in suggesting the vaccine to their patients were thinking high priced and not cost effectiveness of the vaccine (51.6%) and inducing unprotected, risky sexual intercourses (45.9%). CONCLUSION: In this study we determine the professional acception of HPV vaccine between students. Also we determine the most important factor in suggesting the HPV vaccine is the cost effectiveness of it.

Özet

AMAÇ: Araştırmanın amacı, bir tıp fakültesinde kadın hastalıkları ve doğum stajı yapmış öğrencilerin HPV aşısı hakkındaki bilgilerini ve mesleki yaşamlarında aşıyı hastalara önerme eğilimlerini belirlemektir. YÖNTEM: Tanımlayıcı tipteki araştırma bir tıp fakültesinde Kadın Hastalıkları ve Doğum stajını yapmış 166 öğrenci ile yürütüldü. Araştırmanın verileri 3 bölüm halinde hazırlanmış olan ve 30 sorudan oluşan bir anket yolu ile toplandı. İstatistiksel analizde tanımlayıcı istatistikler kullanıldı. BULGULAR: Katılımcı öğrencilerin %55,4’ü kendini HPV aşısı konusunda bilgili hissettiğini belirtirken, %72,9’u HPV’nin kadınlar için daha önemli olduğunu belirtti. Katılımcıların %95,8’i HPV aşısını hastalarına önermeyi düşündüğünü belirtirken, en çok (%51,6) ergenlik çağındaki genç kızlara önermeyi düşünüyorlardı. Öğrencilerin %80,5’i HPV aşısının bedava olmasının önerme ihtimallerini arttıracağını belirtmişti. Aşıyı önerenlerin en çekindikleri noktalar aşının çok pahalı, maliyet etkili olmaması (%51,6) ve korunmasız, riskli cinsel ilişkiyi teşvik edebileceğini (%45,9) düşünmeleriydi. SONUÇ: Araştırmamızda HPV aşısının öğrenciler arasında mesleki olarak kabul gördüğü ve aşının önerilmesindeki en önemli çekincenin aşının maliyet etkililiği olduğu belirlenmiştir.

🔖

Cite This Article

ÖNSÜZ, M. F., TOPUZOĞLU, A., BİLGİ, Z., YILMAZ, M., AMUK, N., FAHRİDİN, F. (2011). The evaluation of the knowledge levels and attitudes of medical students who have accomplished obstetric and gynaecological diseases internship in a medical school about human papilloma virus vaccine. TSK Koruyucu Hekimlik Bülteni, Cilt: 10 - Sayı: 5, 557–564. https://ajindex.com/articles/129235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. 1 Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003
  2. 2 Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest. 2002
  3. 3 Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003
  4. 4 Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2005
  5. 5 Kahn JA, Bernstein DI. Human papillomavirus vaccines. Pediatr Infect Dis J. 2003
  6. 6 Shaw AR. Human papillomavirus vaccines in development: If they’re successful in clinical trials, how will they be implemented? Gynecologic Oncology. 2005
  7. S246-248. 7 Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006
  8. 8 Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002
  9. 9 Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005
  10. 10 Ault KA. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007
  11. 11 Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007
  12. 12 Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 2006
  13. 24(3): 122-131. 13 Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000
  14. 14 Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health